Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015.

Egilman AC, Wallach JD, Ross JS, Dhruva SS.

JAMA Intern Med. 2018 Jan 16. doi: 10.1001/jamainternmed.2017.8016. [Epub ahead of print] No abstract available.

PMID:
29340562
2.

New and incremental FDA black box warnings from 2008 to 2015.

Solotke MT, Dhruva SS, Downing NS, Shah ND, Ross JS.

Expert Opin Drug Saf. 2018 Feb;17(2):117-123. doi: 10.1080/14740338.2018.1415323. Epub 2017 Dec 17.

PMID:
29215916
3.

Systolic Blood Pressure Response in SPRINT (Systolic Blood Pressure Intervention Trial) and ACCORD (Action to Control Cardiovascular Risk in Diabetes): A Possible Explanation for Discordant Trial Results.

Huang C, Dhruva SS, Coppi AC, Warner F, Li SX, Lin H, Nasir K, Krumholz HM.

J Am Heart Assoc. 2017 Nov 13;6(11). pii: e007509. doi: 10.1161/JAHA.117.007509.

4.

Association between FDA black box warnings and Medicare formulary coverage changes.

Dhruva SS, Karaca-Mandic P, Shah ND, Shaw DL, Ross JS.

Am J Manag Care. 2017 Sep 1;23(9):e310-e315.

5.

Medicare Formulary Coverage Restrictions for Prescription Opioids, 2006 to 2015.

Samuels EA, Ross JS, Dhruva SS.

Ann Intern Med. 2017 Dec 19;167(12):895-896. doi: 10.7326/M17-1823. Epub 2017 Oct 10. No abstract available.

PMID:
29052693
6.

Requiem for a Scaffold.

Dhruva SS, Curtis JP.

Ann Intern Med. 2017 Nov 7;167(9):675-676. doi: 10.7326/M17-2522. Epub 2017 Oct 17. No abstract available.

PMID:
29049832
7.

2017 Update on Medical Overuse: A Systematic Review.

Morgan DJ, Dhruva SS, Coon ER, Wright SM, Korenstein D.

JAMA Intern Med. 2018 Jan 1;178(1):110-115. doi: 10.1001/jamainternmed.2017.4361.

PMID:
28973402
8.

Coronary Computed Tomography Angiography vs Functional Stress Testing for Patients With Suspected Coronary Artery Disease: A Systematic Review and Meta-analysis.

Foy AJ, Dhruva SS, Peterson B, Mandrola JM, Morgan DJ, Redberg RF.

JAMA Intern Med. 2017 Nov 1;177(11):1623-1631. doi: 10.1001/jamainternmed.2017.4772. Review.

PMID:
28973101
9.

Merits of Data Sharing: The Digitalis Investigation Group Trial.

Angraal S, Ross JS, Dhruva SS, Desai NR, Welsh JW, Krumholz HM.

J Am Coll Cardiol. 2017 Oct 3;70(14):1825-1827. doi: 10.1016/j.jacc.2017.07.786. No abstract available.

PMID:
28958337
10.

The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States.

Gupta R, Dhruva SS, Fox ER, Ross JS.

J Manag Care Spec Pharm. 2017 Oct;23(10):1066-1076. doi: 10.18553/jmcp.2017.23.10.1066.

11.

Author's Response.

Coon ER, Young PC, Quinonez RA, Morgan DJ, Dhruva SS, Schroeder AR.

Pediatrics. 2017 Sep;140(3). pii: e20172108. doi: 10.1542/peds.2017-2108B. No abstract available.

PMID:
28860137
12.

Characteristics of Clinical Studies Used for US Food and Drug Administration Approval of High-Risk Medical Device Supplements.

Zheng SY, Dhruva SS, Redberg RF.

JAMA. 2017 Aug 15;318(7):619-625. doi: 10.1001/jama.2017.9414.

PMID:
28810022
13.

Inclusion of Demographic-Specific Information in Studies Supporting US Food & Drug Administration Approval of High-Risk Medical Devices.

Dhruva SS, Mazure CM, Ross JS, Redberg RF.

JAMA Intern Med. 2017 Sep 1;177(9):1390-1391. doi: 10.1001/jamainternmed.2017.3148. No abstract available.

PMID:
28738116
14.

Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).

Dhruva SS, Huang C, Spatz ES, Coppi AC, Warner F, Li SX, Lin H, Xu X, Furberg CD, Davis BR, Pressel SL, Coifman RR, Krumholz HM.

Hypertension. 2017 Jul;70(1):94-102. doi: 10.1161/HYPERTENSIONAHA.117.09221. Epub 2017 May 30.

PMID:
28559399
15.

Real-World Data on Heart Failure Readmission Reduction: Real or Real Uncertain?

Krumholz HM, Dhruva SS.

J Am Coll Cardiol. 2017 May 16;69(19):2366-2368. doi: 10.1016/j.jacc.2017.03.019. Epub 2017 Mar 19. No abstract available.

PMID:
28330750
16.

FDA Drug Trials Snapshots-A Clearer Picture.

Dhruva SS, Redberg RF.

JAMA Intern Med. 2017 May 1;177(5):727. doi: 10.1001/jamainternmed.2017.0037. No abstract available.

PMID:
28288250
18.

Medicare Formulary Changes After the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline.

Dhruva SS, Desai NR, Karaca-Mandic P, Shah ND, Ross JS.

J Am Coll Cardiol. 2017 Jan 17;69(2):244-246. doi: 10.1016/j.jacc.2016.10.053. No abstract available.

19.

Update on Pediatric Overuse.

Coon ER, Young PC, Quinonez RA, Morgan DJ, Dhruva SS, Schroeder AR.

Pediatrics. 2017 Feb;139(2). pii: e20162797. doi: 10.1542/peds.2016-2797. Epub 2017 Jan 3. Review.

20.

Transcatheter Aortic Valve Replacement in Younger Individuals.

Sedrakyan A, Dhruva SS, Shuhaiber J.

JAMA Intern Med. 2017 Feb 1;177(2):159-160. doi: 10.1001/jamainternmed.2016.8104. No abstract available.

PMID:
28027340
21.

For the Patient with "Low-risk Chest Pain"-How Low Is Low?

Foy AJ, Dhruva SS, Mandrola J.

Acad Radiol. 2016 Dec;23(12):1587-1591. doi: 10.1016/j.acra.2016.07.011. Epub 2016 Sep 23. No abstract available.

PMID:
27671908
22.

2016 Update on Medical Overuse: A Systematic Review.

Morgan DJ, Dhruva SS, Wright SM, Korenstein D.

JAMA Intern Med. 2016 Nov 1;176(11):1687-1692. doi: 10.1001/jamainternmed.2016.5381. Review.

23.

Sex-Specific Data for the Subcutaneous Implantable Cardioverter-Defibrillator.

Dhruva SS, Redberg RF.

J Am Coll Cardiol. 2016 Jul 5;68(1):133. doi: 10.1016/j.jacc.2016.02.085. No abstract available.

24.

Championing Effectiveness Before Cost-Effectiveness.

Dhruva SS, Krumholz HM.

JACC Heart Fail. 2016 May;4(5):376-9. doi: 10.1016/j.jchf.2016.02.001. Epub 2016 Mar 30. No abstract available.

25.

The Core Value of Cost-Effectiveness Analyses.

Dhruva SS, Krumholz HM.

J Am Coll Cardiol. 2016 Jan 5;67(1):39-41. doi: 10.1016/j.jacc.2015.11.013. No abstract available.

26.

Application of Medicare's New Technology Add-on Payment Program for Blinatumomab.

Dhruva SS, Prasad V.

JAMA Oncol. 2016 Feb;2(2):165-6. doi: 10.1001/jamaoncol.2015.5359. No abstract available.

PMID:
26720844
27.

Update on Medical Practices That Should Be Questioned in 2015.

Morgan DJ, Dhruva SS, Wright SM, Korenstein D.

JAMA Intern Med. 2015 Dec;175(12):1960-4. doi: 10.1001/jamainternmed.2015.5614. Review.

28.

Revisiting Essure--Toward Safe and Effective Sterilization.

Dhruva SS, Ross JS, Gariepy AM.

N Engl J Med. 2015 Oct 8;373(15):e17. doi: 10.1056/NEJMp1510514. Epub 2015 Sep 23. No abstract available.

29.

Setting a research agenda for medical overuse.

Morgan DJ, Brownlee S, Leppin AL, Kressin N, Dhruva SS, Levin L, Landon BE, Zezza MA, Schmidt H, Saini V, Elshaug AG.

BMJ. 2015 Aug 25;351:h4534. doi: 10.1136/bmj.h4534. No abstract available.

30.

Here Today, Gone Tomorrow.

Sab S, Dhruva SS, Paulsen J, Sidhu RS, Amsterdam EA, Venugopal S.

Am J Med. 2015 Dec;128(12):e7-9. doi: 10.1016/j.amjmed.2015.07.039. Epub 2015 Aug 21. No abstract available.

PMID:
26302138
31.
32.

Evidence And Medicare's Coverage Of Interventions.

Dhruva SS, Redberg RF.

Health Aff (Millwood). 2015 Jun;34(6):1066. doi: 10.1377/hlthaff.2015.0445. No abstract available.

PMID:
26056214
33.

Presumed safe no more: lessons from the Wingspan saga on regulation of devices.

Gartenberg AJ, Peleg A, Dhruva SS, Redberg RF.

BMJ. 2014 Jan 22;348:g93. doi: 10.1136/bmj.g93. No abstract available.

PMID:
24452627
34.

FDA regulation of cardiovascular devices and opportunities for improvement.

Dhruva SS, Redberg RF.

J Interv Card Electrophysiol. 2013 Mar;36(2):99-105. doi: 10.1007/s10840-012-9767-1. Epub 2012 Dec 21.

PMID:
23263896
35.

Inclusion of comparative effectiveness data in high-risk cardiovascular device studies at the time of premarket approval.

Chen CE, Dhruva SS, Redberg RF.

JAMA. 2012 Nov 7;308(17):1740-2. doi: 10.1001/jama.2012.14491. No abstract available.

PMID:
23117769
36.

Medical device regulation: time to improve performance.

Dhruva SS, Redberg RF.

PLoS Med. 2012;9(7):e1001277. doi: 10.1371/journal.pmed.1001277. Epub 2012 Jul 31. No abstract available.

37.

Evaluating sex differences in medical device clinical trials: time for action.

Dhruva SS, Redberg RF.

JAMA. 2012 Mar 21;307(11):1145-6. doi: 10.1001/jama.2012.254. Epub 2012 Feb 29. No abstract available.

PMID:
22378695
38.

Withdrawing unsafe drugs from the market.

Dhruva SS, Redberg RF.

Health Aff (Millwood). 2011 Nov;30(11):2218. doi: 10.1377/hlthaff.2011.1106. No abstract available.

PMID:
22068420
39.

Sex-specific outcomes for HeartMate II.

Dhruva SS, Redberg RF.

J Am Coll Cardiol. 2011 Sep 13;58(12):1285; author reply 1285-6. doi: 10.1016/j.jacc.2011.05.039. No abstract available.

40.

Transcatheter aortic-valve replacement.

Redberg RF, Dhruva SS.

N Engl J Med. 2011 Sep 8;365(10):958-9; author reply 959. doi: 10.1056/NEJMc1108223#SA1. No abstract available.

PMID:
21899458
41.

Clinical trial enrollment and progress in women's health.

Dhruva SS, Redberg RF.

JAMA. 2011 Mar 23;305(12):1197; author reply 1197-8. doi: 10.1001/jama.2011.347. No abstract available.

PMID:
21427370
42.

Gender bias in studies for Food and Drug Administration premarket approval of cardiovascular devices.

Dhruva SS, Bero LA, Redberg RF.

Circ Cardiovasc Qual Outcomes. 2011 Mar;4(2):165-71. doi: 10.1161/CIRCOUTCOMES.110.958215. Epub 2011 Mar 1. Review.

43.

Medical device recalls: get it right the first time: Comment on "Medical device recalls and the FDA approval process".

Redberg RF, Dhruva SS.

Arch Intern Med. 2011 Jun 13;171(11):1011-2. doi: 10.1001/archinternmed.2011.27. Epub 2011 Feb 14. No abstract available.

PMID:
21321286
44.

Inclusion of training patients in US Food and Drug Administration premarket approval cardiovascular device studies.

Chen CE, Dhruva SS, Bero LA, Redberg RF.

Arch Intern Med. 2011 Mar 28;171(6):534-9. doi: 10.1001/archinternmed.2010.445. Epub 2010 Nov 22.

PMID:
21098342
45.

Accelerated approval and possible withdrawal of midodrine.

Dhruva SS, Redberg RF.

JAMA. 2010 Nov 17;304(19):2172-3. doi: 10.1001/jama.2010.1695. No abstract available.

PMID:
21081731
46.

The need for sex-specific data prior to food and drug administration approval.

Dhruva SS, Redberg RF.

J Am Coll Cardiol. 2010 Jan 19;55(3):261; author reply 261-2. doi: 10.1016/j.jacc.2009.08.053. No abstract available.

47.

Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices.

Dhruva SS, Bero LA, Redberg RF.

JAMA. 2009 Dec 23;302(24):2679-85. doi: 10.1001/jama.2009.1899. Review. Erratum in: JAMA. 2010 Feb 3;303(5):422.

PMID:
20040556
48.

CMS's landmark decision on CT colonography--examining the relevant data.

Dhruva SS, Phurrough SE, Salive ME, Redberg RF.

N Engl J Med. 2009 Jun 25;360(26):2699-701. doi: 10.1056/NEJMp0904408. Epub 2009 May 27. No abstract available.

49.

Variations between clinical trial participants and Medicare beneficiaries in evidence used for Medicare national coverage decisions.

Dhruva SS, Redberg RF.

Arch Intern Med. 2008 Jan 28;168(2):136-40. doi: 10.1001/archinternmed.2007.56. Erratum in: Arch Intern Med. 2008 Apr 14;168(7):774.

PMID:
18227358

Supplemental Content

Loading ...
Support Center